 Jeffrey Olsen
Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 12 | 2024 | 158 | 3.970 |
Why?
| | Chemoradiotherapy | 12 | 2024 | 239 | 2.560 |
Why?
| | Radiosurgery | 8 | 2020 | 401 | 2.170 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2019 | 142 | 1.760 |
Why?
| | Gastrointestinal Neoplasms | 6 | 2020 | 70 | 1.660 |
Why?
| | Anus Neoplasms | 3 | 2019 | 32 | 1.620 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2020 | 149 | 1.620 |
Why?
| | Neoadjuvant Therapy | 11 | 2024 | 463 | 1.580 |
Why?
| | Liver Neoplasms | 8 | 2020 | 783 | 1.490 |
Why?
| | Adenocarcinoma | 11 | 2024 | 931 | 1.320 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2019 | 372 | 1.170 |
Why?
| | Radiotherapy, Image-Guided | 5 | 2020 | 39 | 1.110 |
Why?
| | Radiation Oncology | 4 | 2025 | 89 | 1.000 |
Why?
| | Esophageal Neoplasms | 4 | 2024 | 349 | 0.910 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 642 | 0.900 |
Why?
| | Pancreatic Neoplasms | 8 | 2022 | 927 | 0.880 |
Why?
| | Imagination | 1 | 2024 | 21 | 0.820 |
Why?
| | Technology | 1 | 2024 | 96 | 0.780 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1958 | 0.730 |
Why?
| | Prostatic Neoplasms | 4 | 2015 | 978 | 0.720 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2738 | 0.720 |
Why?
| | Colorectal Neoplasms | 3 | 2021 | 848 | 0.690 |
Why?
| | Magnetic Resonance Imaging | 7 | 2021 | 3869 | 0.660 |
Why?
| | Radiotherapy Dosage | 8 | 2020 | 289 | 0.660 |
Why?
| | Magnetic Resonance Imaging, Interventional | 2 | 2019 | 29 | 0.630 |
Why?
| | Thoracic Neoplasms | 2 | 2016 | 39 | 0.600 |
Why?
| | Lymphatic Irradiation | 1 | 2019 | 10 | 0.600 |
Why?
| | Abdominal Neoplasms | 2 | 2016 | 47 | 0.590 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2012 | 269 | 0.550 |
Why?
| | Deglutition Disorders | 1 | 2018 | 147 | 0.500 |
Why?
| | Intestine, Small | 2 | 2017 | 166 | 0.490 |
Why?
| | Organs at Risk | 5 | 2020 | 37 | 0.490 |
Why?
| | Tumor Burden | 6 | 2018 | 322 | 0.490 |
Why?
| | Humans | 52 | 2025 | 144957 | 0.430 |
Why?
| | Fluorouracil | 5 | 2019 | 235 | 0.430 |
Why?
| | Aged, 80 and over | 16 | 2019 | 8279 | 0.430 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2012 | 162 | 0.420 |
Why?
| | Multimodal Imaging | 2 | 2012 | 129 | 0.420 |
Why?
| | Catheter Ablation | 1 | 2018 | 353 | 0.420 |
Why?
| | Induction Chemotherapy | 4 | 2024 | 87 | 0.410 |
Why?
| | Neoplasms | 2 | 2020 | 2884 | 0.400 |
Why?
| | Positron-Emission Tomography | 2 | 2012 | 343 | 0.400 |
Why?
| | Prostate-Specific Antigen | 1 | 2013 | 162 | 0.380 |
Why?
| | Prone Position | 1 | 2012 | 24 | 0.370 |
Why?
| | Supine Position | 1 | 2012 | 37 | 0.370 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1141 | 0.350 |
Why?
| | Serpins | 1 | 2010 | 28 | 0.330 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 285 | 0.320 |
Why?
| | Middle Aged | 22 | 2024 | 35928 | 0.300 |
Why?
| | Movement | 2 | 2011 | 294 | 0.300 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1322 | 0.300 |
Why?
| | Radiopharmaceuticals | 3 | 2018 | 207 | 0.290 |
Why?
| | Aged | 19 | 2024 | 25947 | 0.290 |
Why?
| | Diagnostic Imaging | 2 | 2024 | 339 | 0.290 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 272 | 0.290 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 583 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 1182 | 0.280 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 466 | 0.280 |
Why?
| | Mitomycin | 2 | 2019 | 32 | 0.280 |
Why?
| | Tomography, Spiral Computed | 1 | 2007 | 30 | 0.270 |
Why?
| | Lung Neoplasms | 5 | 2013 | 2642 | 0.270 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1465 | 0.260 |
Why?
| | Yttrium Radioisotopes | 2 | 2018 | 64 | 0.260 |
Why?
| | Respiration | 1 | 2007 | 207 | 0.250 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2197 | 0.240 |
Why?
| | Disease-Free Survival | 4 | 2017 | 769 | 0.230 |
Why?
| | Radiotherapy | 2 | 2017 | 206 | 0.230 |
Why?
| | Algorithms | 3 | 2015 | 1839 | 0.220 |
Why?
| | Risk Management | 1 | 2025 | 84 | 0.220 |
Why?
| | Embolization, Therapeutic | 2 | 2018 | 242 | 0.220 |
Why?
| | Combined Modality Therapy | 3 | 2024 | 1268 | 0.210 |
Why?
| | Medical Errors | 1 | 2025 | 118 | 0.210 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 334 | 0.210 |
Why?
| | Treatment Outcome | 9 | 2023 | 11695 | 0.210 |
Why?
| | Preoperative Care | 2 | 2017 | 380 | 0.200 |
Why?
| | Pancreas | 2 | 2023 | 342 | 0.190 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 781 | 0.190 |
Why?
| | Organoplatinum Compounds | 3 | 2017 | 66 | 0.190 |
Why?
| | Leucovorin | 3 | 2017 | 101 | 0.190 |
Why?
| | Patient Safety | 1 | 2025 | 349 | 0.180 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1325 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 966 | 0.170 |
Why?
| | Medical Oncology | 1 | 2024 | 332 | 0.170 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 31 | 0.150 |
Why?
| | Adult | 13 | 2024 | 40506 | 0.150 |
Why?
| | Male | 18 | 2024 | 72406 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5417 | 0.150 |
Why?
| | Stomach | 2 | 2016 | 109 | 0.150 |
Why?
| | Workflow | 2 | 2020 | 185 | 0.150 |
Why?
| | Duodenum | 2 | 2016 | 77 | 0.150 |
Why?
| | Female | 17 | 2024 | 78376 | 0.140 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 2018 | 6 | 0.140 |
Why?
| | Serum Albumin, Human | 1 | 2018 | 7 | 0.140 |
Why?
| | Bilirubin | 1 | 2018 | 97 | 0.140 |
Why?
| | Rectum | 3 | 2020 | 180 | 0.140 |
Why?
| | Observer Variation | 2 | 2015 | 355 | 0.130 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2018 | 89 | 0.130 |
Why?
| | Matched-Pair Analysis | 1 | 2017 | 37 | 0.130 |
Why?
| | Colon | 2 | 2017 | 305 | 0.130 |
Why?
| | Precision Medicine | 1 | 2021 | 458 | 0.130 |
Why?
| | Age Factors | 2 | 2017 | 3335 | 0.120 |
Why?
| | Microspheres | 1 | 2016 | 142 | 0.120 |
Why?
| | Pelvis | 1 | 2017 | 124 | 0.120 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 24 | 0.110 |
Why?
| | Camptothecin | 1 | 2016 | 140 | 0.110 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2015 | 28 | 0.110 |
Why?
| | Liposarcoma | 1 | 2015 | 31 | 0.110 |
Why?
| | ROC Curve | 1 | 2017 | 615 | 0.110 |
Why?
| | Regression Analysis | 1 | 2017 | 1003 | 0.110 |
Why?
| | Lung | 1 | 2007 | 4109 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2015 | 151 | 0.100 |
Why?
| | Retrospective Studies | 9 | 2024 | 17101 | 0.100 |
Why?
| | Prostate | 2 | 2015 | 158 | 0.100 |
Why?
| | Acute Disease | 1 | 2017 | 1031 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1563 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 20 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2015 | 208 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2017 | 1095 | 0.090 |
Why?
| | Motion | 1 | 2012 | 100 | 0.090 |
Why?
| | Thoracic Wall | 1 | 2012 | 21 | 0.090 |
Why?
| | Patient Positioning | 1 | 2012 | 70 | 0.090 |
Why?
| | Karnofsky Performance Status | 1 | 2011 | 37 | 0.090 |
Why?
| | Image Enhancement | 1 | 2012 | 199 | 0.090 |
Why?
| | Pneumonectomy | 1 | 2013 | 169 | 0.080 |
Why?
| | Computer Systems | 1 | 2011 | 56 | 0.080 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2011 | 140 | 0.080 |
Why?
| | Rotation | 1 | 2011 | 121 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 509 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 689 | 0.080 |
Why?
| | Survival Rate | 3 | 2024 | 2092 | 0.080 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 39 | 0.080 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 562 | 0.080 |
Why?
| | Software | 2 | 2016 | 692 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 1385 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1311 | 0.070 |
Why?
| | Capecitabine | 2 | 2020 | 57 | 0.070 |
Why?
| | Inhalation | 1 | 2007 | 29 | 0.070 |
Why?
| | Exhalation | 1 | 2007 | 29 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1990 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1291 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 139 | 0.060 |
Why?
| | Prognosis | 2 | 2018 | 4293 | 0.060 |
Why?
| | Pain | 1 | 2012 | 782 | 0.060 |
Why?
| | Deoxycytidine | 2 | 2019 | 221 | 0.060 |
Why?
| | Bile Duct Neoplasms | 1 | 2007 | 128 | 0.060 |
Why?
| | Cohort Studies | 2 | 2016 | 5965 | 0.060 |
Why?
| | Esophagogastric Junction | 1 | 2024 | 56 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3415 | 0.050 |
Why?
| | Quality of Life | 1 | 2016 | 3192 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1540 | 0.050 |
Why?
| | Trypanosoma brucei rhodesiense | 1 | 2002 | 1 | 0.050 |
Why?
| | Trypanocidal Agents | 1 | 2002 | 2 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3676 | 0.050 |
Why?
| | Diphosphonates | 1 | 2002 | 68 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 118 | 0.040 |
Why?
| | Paclitaxel | 1 | 2022 | 256 | 0.040 |
Why?
| | Watchful Waiting | 1 | 2021 | 89 | 0.040 |
Why?
| | Brachytherapy | 1 | 2020 | 134 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2020 | 340 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 631 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 85 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 531 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7183 | 0.030 |
Why?
| | Duodenal Ulcer | 1 | 2016 | 12 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 382 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 72 | 0.030 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2015 | 20 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1054 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2015 | 30 | 0.030 |
Why?
| | Perioperative Period | 1 | 2015 | 71 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 117 | 0.030 |
Why?
| | Neutropenia | 1 | 2016 | 155 | 0.030 |
Why?
| | Penis | 1 | 2015 | 32 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 548 | 0.030 |
Why?
| | United States | 2 | 2025 | 15988 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 188 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1721 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 205 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 334 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 421 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 216 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 489 | 0.020 |
Why?
| | Pancreatectomy | 1 | 2016 | 285 | 0.020 |
Why?
| | Urinary Bladder | 1 | 2015 | 194 | 0.020 |
Why?
| | Sarcoma | 1 | 2015 | 205 | 0.020 |
Why?
| | Neutrophils | 1 | 2018 | 1134 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1888 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 365 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2016 | 705 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 695 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4275 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2118 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1077 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 1026 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2852 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2119 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7997 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2016 | 2920 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10792 | 0.010 |
Why?
| | Lethal Dose 50 | 1 | 2002 | 15 | 0.010 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2002 | 20 | 0.010 |
Why?
| | Quantum Theory | 1 | 2002 | 93 | 0.010 |
Why?
| | Crystallography, X-Ray | 1 | 2002 | 493 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 919 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1619 | 0.010 |
Why?
| | Animals | 1 | 2002 | 38109 | 0.000 |
Why?
|
|
Olsen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|